Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Scripps scientists studying sepsis in mice find potential drug targets for deadly disease

Scripps scientists studying sepsis in mice find potential drug targets for deadly disease

February 28, 2008

"We have identified a key connection of signaling pathways in the cascade of events leading to sepsis. This defines a crucial point where the immune system spirals out of control to cause severe sepsis and where there is an opportunity for therapeutic intervention," says Scripps Research Professor Wolfram Ruf, who led the research with his postdoctoral fellow Frank Niessen. Their results are published in the February 27 advance, online issue of Nature.

Ruf and his colleagues identified a new cross talk involving the vascular coagulation system and certain cells in the immune system. By disrupting this cross talk, they were able to rescue mice from death due to sepsis. Though there is no guarantee this preclinical success will translate into human therapies, these proof-of-principle experiments may improve the diagnosis of heterogeneous sepsis syndromes and yield potent drugs for treating people who suffer from sepsis.




A Severe, Fast-Moving Disease

Sepsis is a severe, fast-moving, dramatic, and often fatal disease caused by an overwhelming bacterial infection that enters the bloodstream. These invading bacteria produce endotoxins and other toxic chemicals that trigger a widespread inflammatory response of the innate immune system-a response that is necessary, as it turns out, because without the inflammation, the body cannot fight off the bacterial infection.

Unfortunately, this inflammation can also spiral out of control leading to septic shock. During sepsis, the inflammation triggers widespread coagulation in the bloodstream. This coagulation can block blood vessels in vital organs, starving the organs of oxygen and damaging them. The organs can be further damaged when the blood starts to flow again because the lining of the blood vessels remain leaky due to inflammatory cytokines and damage by intravascular coagulation. This leads to edema, the buildup of liquid in tissues and allows immune cells to exit the bloodstream and enter the tissue. Inside the tissues, the immune cells can cause severe damage and organ failure. Frequently, the vital function of kidneys and lungs are affected.

Sepsis syndrome can be either fulminant or protracted when patients are not able to cope with and to recover from severe infections. Overall, the prognosis for sepsis is dire. It is one of the leading causes of death for both infants and adults in the United States, and, according to the Centers for Disease Control and Prevention (CDC), it accounted for more than 33,000 deaths in 2004 alone-the last year for which complete statistics are available.

Numerous therapeutic approaches to treating sepsis have been tried through the years. For many years, the only option was to administer powerful, broad-spectrum antibiotics to control the bacterial infection. By the time these were administered, however, it was often too late. The antibiotics did not affect the existing bacterial toxins in the bloodstream, and they could not counter what appeared to be a self perpetuating inflammatory response that results from these toxins. Therapeutic approaches that attempt to reduce inflammation have proven to make people worse off than they were without treatment because those therapies compromise the immune response, unshackling the bacteria in the process.

Another possible approach to intervention involves exploiting the connection between coagulation and immunity, and anticoagulants have proven to be an effective treatment in severe sepsis. In recent years, the U.S. Food and Drug Administration (FDA) approved a recombinant form of activated protein C (Xigris) for treating sepsis, which is believed to work, in part, by controlling coagulation. However, other anticoagulants have failed in clinical trials and recent experiments in mice indicate that Xigris protects the vascular endothelium directly through cell signaling, rather than regulating coagulation.

A New View of Sepsis

The coagulation cascade is a tightly controlled mechanism designed primarily to prevent blood loss due to injury, but is also aberrantly activated in diseases like Ebola and sepsis. Though the link between coagulation and inflammation is one that scientists have known about for years, the exact molecules that connect coagulation to the inflammatory response in sepsis have remained a mystery. Ruf and his colleagues, wanting to understand the process, turned to knockout mice missing signaling receptors for coagulation enzymes, called the protease activated receptors (PARs).

Specifically, they found that mice lacking PAR1, also known as the thrombin receptor, were less likely to die from sepsis. Surprisingly, PAR1-deficient animals initially became very sick when exposed to endotoxin, but recovered more quickly from systemic inflammation and thereby escaped the deadly complication of sepsis syndrome. It turned out that normal mice could also be rescued from death when they received pharmacological drugs that block the PAR1 receptor or very high doses of coagulation inhibitors. This therapeutic intervention was successful, even when inflammation had already peaked. These experiments provided the first clue to indicate that it is the cell signaling component of the coagulation cascade that triggers severe systemic inflammatory response syndromes.

It was originally believed that coagulation in the blood stream damages endothelial cells that line the vasculature. This damage, in turn, helps activate platelets and leucocytes to cause thrombosis and organ damage. Ruf and his colleagues discovered that -unexpectedly-coagulation activates the immune system directly to promote sepsis syndrome. In particular, the dendritic cells of the mouse's immune system play an important role and these cells are perturbed in the lymphatic system, rather than in the blood stream.

Typically dendritic cells produce potent pro-inflammatory cytokines in the lymph nodes during immune reactions. When the dendritic cells sense the increased coagulation in sepsis, they migrate faster through the lymphatic system and as a result do not stay put in the lymph nodes. This causes a release of inflammatory cytokines and chemical signals directly into the lymph. Lymphatic fluid is constantly recycled into the blood stream through the thoracic duct. This major lymph vessel connects to the blood stream immediately before blood enters the lungs. In sepsis, inflammatory mediators in the lymph fluid are thereby directly delivered to one of the most vital organs in the body.

In further research of this novel sepsis mechanism, Ruf and his colleagues uncovered downstream components of the PAR1 signaling pathway. Making use of chemical probes provided by the Scripps Molecular Screening Center, they identified that protease signaling on the dendritic cells induces the production of sphingosine 1 phosphate (S1P), a bioactive lipid that activates another G protein-couples receptor, the S1P receptor 3 (S1P3). In mice that lacked this receptor, they showed that dendritic cells are also responsible for triggering disseminated intravascular coagulation in sepsis. Through the connection between S1P3 and PAR1, dendritic cells are caught in an amplification circuit whereby they activate coagulation, and are in turn excited by one of the enzymes in the coagulation cascade to produce severe systemic inflammation.

Ruf and his colleagues showed that interrupting the S1P3 and PAR1 communication not only prevents the spread of inflammation though the body, but confines the inflammatory reaction to a desired location: the lymph node where the immune system fights microorganisms. This research provides a new view of sepsis and identifies potential targets that might restore a beneficial inflammatory response while blocking the deadly consequences of sepsis. The researchers are now evaluating which targets would be most amenable to clinical development and are testing the broader relevance of this pathway for other infectious diseases.

Scripps Research Institute



Related Sepsis Current Events and Sepsis News Articles Sepsis Current Events and Sepsis News RSS Sepsis Current Events and Sepsis News RSS
A Second Skin
Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections.

Progress made on group B streptococcus vaccine
Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible.

Canadian scientists link fat hormone to death from potentially deadly blood infection
A new Canadian study has found that lower-than-normal levels of a naturally-occurring fat hormone may increase the risk of death from sepsis-an overwhelming infection of the blood which claims thousands of lives each year.

OMRF scientists discover promising new path for treating traumas
A discovery by scientists at the Oklahoma Medical Research Foundation could help save lives threatened by traumatic injuries like those sustained in car crashes or on the battlefield. The work also holds potential for treating severe infectious diseases and diabetes.

Scientists create NICE solution to pneumonia vaccine testing problems
Medical clinics the world over could benefit from new software* created at the National Institute of Standards and Technology (NIST), where a team of scientists has found a way to improve the efficiency of a pneumonia vaccine testing method developed at the University of Alabama at Birmingham (UAB).

Compound shows potential for slowing progression of ALS
A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice.

Review: Pneumococcal conjugate vaccines effective at preventing child deaths
A study published in The Cochrane Review this month concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and x-ray defined pneumonia, was also effective against child deaths.

Key feature of immune system survived in humans, other primates for 60 million years
A new study has concluded that one key part of the immune system, the ability of vitamin D to regulate anti-bactericidal proteins, is so important that is has been conserved through almost 60 million years of evolution and is shared only by primates, including humans - but no other known animal species.

Discovery may lead to powerful new therapy for asthma
University of Texas Medical Branch at Galveston researchers have found that a single enzyme is apparently critical to most allergen-provoked asthma attacks - and that activity of the enzyme, known as aldose reductase, can be significantly reduced by compounds that have already undergone clinical trials as treatments for complications of diabetes.

Abnormal Brain Circuits May Prevent Movement Disorder
Most people who carry a genetic mutation for a movement disorder called dystonia will never develop symptoms, a phenomenon that has puzzled scientists since the first genetic mutation was identified in the 1990's.
More Sepsis Current Events and Sepsis News Articles
Sepsis and Non-infectious Systemic Inflammation: From Biology to Critical Care

Sepsis and Non-infectious Systemic Inflammation: From Biology to Critical Care
by Jean-Marc Cavaillon (Editor), Christophe Adrie (Editor)

Providing definitions, clinical features and epidemiology, Sepsis and Non-infectious Systemic Inflammation adopts a comprehensive approach, describing in detail the various physiological systems involved. As such, this unique handbook and reference work is the first to combine sepsis and non-infectious SIRS, reviewing both the biological and medical aspects of these two important syndromes. The whole is rounded off with a discussion of past, present and future therapies.

Sepsis: New Strategies for Management

Sepsis: New Strategies for Management
by Jordi Rello (Editor), Marcos I. Restrepo (Editor)

Sepsis is an important public health problem around the world. Severe sepsis carries significant morbidity, mortality and high costs. The incidence of sepsis is increasing because of the aging population, the growing number of immunocompromised hosts, the increasing use of invasive procedures, and, to a lesser extent, antibiotic resistance among pathogens. Despite recent advances in the pathogenesis, diagnosis, and therapeutic approaches the mortality rate associated with this condition remains high. Therefore, the goal of "Sepsis: New Strategies" is to review novel targets to be considered in patients with severe sepsis and to assess new developments for patients with sepsis originating in the respiratory tract.

Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery (Update in Intensive Care Medicine)

Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery (Update in Intensive Care Medicine)
by Edward Abraham (Editor), Mervyn Singer (Editor)

There have been tremendous advances in understanding the cellular mechanisms involved in sepsis and contributing to the development of multiple organ dysfunction and mortality in this setting. The chapters in this book provide up-to-date insights into important pathways that are initiated by sepsis.

Deep Sea Creatures

Deep Sea Creatures
by Monstrum Sepsis
Monstrum Sepsis (Performer)

Monstrum Sepsis emerges from the depths to bring you a new full length album of exquisitely inspired and arranged electronic music. Written and composed by Rob Wentz with additional instrumentation from Paul Karlik and guest vocals from Shikhee of Android Lust. Originally limited to 300 copies this new pressing features a few artwork enhancements as well as two new tracks. These 12 tracks will lift you off your feet in a sonic array of pulsing synthetics, disruptive modulations, sweeping strings and incredibly infectious rhythms.

Primordial Notions Delta 2001-2004

Primordial Notions Delta 2001-2004
Monstrum Sepsis (Primary Contributor)



  Bacteria Sepsis: Video 1 of 3 [VHS]
Starring: Diane Charsha



Management of Sepsis: the PIRO Approach

Management of Sepsis: the PIRO Approach
by Jordi Rello (Editor), Emili Díaz (Editor), Alejandro Rodríguez (Editor)

Sepsis is a very important public health problem. It is widely acknowledged that the severe inflammatory response syndrome/severe sepsis paradigm fails to stratify sepsis patients adequately. This book reviews in detail how sepsis should be managed on the basis of a novel approach to staging. The PIRO (predisposing factors, infection, response, organ dysfunction) model was first proposed at the start of the decade on a theoretical basis and has now been translated into a practical approach for use at the bedside. It is loosely based on the TNM staging system for cancers, with points being allocated to each of the four aforementioned key characteristics of the septic process. The proposed PIRO framework facilitates evaluation of factors that are important in the pathogenesis of severe...

Sepsis (Competency-Based Critical Care)

Sepsis (Competency-Based Critical Care)
by Simon V. Baudouin (Editor)

Sepsis is a serious medical condition, resulting from the immune response to a severe infection. Septicaemia is sepsis of the bloodstream caused by bactemeria, which is the presence of bacteria in the bloodstream. The term septecaemia is also used to refer to sepsis in general. In the US, sepsis is the leading cause of death in non-coronary ICU patients, and the tenth most common form of death overall. Sepsis is common and also more dangerous in the elderly, immunocompromised, and critically ill patients. It occurs in 1-2% of all hospitilizations and accounts for as much as 25% of all ICU bed utilization. It is a major cause of death in intensive care units worldwide, with mortality rates that range from 20% for sepsis to 40% for severe sepsis to more than 60% for septic shock. The...

Impact 1.5 250 ml Cans, 24/cs (202.8 oz/cs)

Impact 1.5 250 ml Cans, 24/cs (202.8 oz/cs)
by Novartis

IMPACT 1.5 is a calorically dense, patented enteral formula containing arginine, dietary nucleotides and fish oil. Each member of the Impact family of products has a unique and patented formula that has been demonstrated in clinical trials to improve patient outcomes. Specifically, patients who received an Impact formula in clinical trials developed fewer infections and had shorter hospital stays than those patients fed enteral formulas. Impact 1.5 formula is intended for patients with fluid restrictions or high energy needs. Impact 1.5 is a Medical Food- consumers should consult with their physician on the use of this product. 250 ml Cans, 24/Case (202.8 oz/Case) Provides nutritional support for immuno compromised patients who require fluid restriction or have higher energy needs such...

Primordial Notions Gamma 1996-2000

Primordial Notions Gamma 1996-2000
Monstrum Sepsis (Primary Contributor)



© 2009 BrightSurf.com